Residency · Residency · Family Medicine

Dyslipidemia Beyond Statins

Overview

While statins remain the cornerstone of lipid-lowering therapy, the therapeutic landscape has expanded considerably. Non-statin agents are now available for patients with statin intolerance, inadequate LDL reduction on maximally tolerated statins, or specific lipid disorders such as severe hypertriglyceridemia and familial hypercholesterolemia. Understanding when and how to deploy these therapies is an increasingly important skill for the family physician.

Lipid Panel Interpretation

LDL cholesterol is the primary target for ASCVD risk reduction. Low HDL is a risk marker, but pharmacologically raising HDL has not reduced cardiovascular events in clinical trials. Triglycerides become clinically significant above 150 mg/dL and pose a pancreatitis risk above 500 mg/dL. Non-HDL cholesterol (total cholesterol minus HDL) captures all atherogenic particles including LDL and VLDL, making it a useful secondary target, particularly when triglycerides are elevated. Apolipoprotein B provides a single measurement reflecting all atherogenic particles and may be more accurate than calculated LDL-C. Lipoprotein(a) is a genetically determined, independent cardiovascular risk factor that should be checked once in a lifetime; no approved Lp(a)-lowering therapy exists yet, though trials are underway.

Statin Therapy Review

Guideline-Based Statin Indications (2018 ACC/AHA)

The four statin benefit groups are: clinical ASCVD (high-intensity statin for secondary prevention), LDL 190 mg/dL or above (high-intensity statin, with evaluation for familial hypercholesterolemia), diabetes aged 40 to 75 (moderate-intensity, escalated to high-intensity with multiple risk factors), and primary prevention with 10-year ASCVD risk of 7.5% or above in patients aged 40 to 75 (moderate-to-high intensity after risk discussion).

Statin Side Effects

Myalgias occur in 5 to 10% of patients in practice, though blinded trials suggest much of this is nocebo effect. Rhabdomyolysis is rare (below 0.1%). Baseline ALT should be checked, but routine liver monitoring is no longer recommended unless symptoms suggest hepatotoxicity. A modest increase in new-onset diabetes occurs (approximately 1 per 255 patients over 4 years), but the cardiovascular benefit outweighs this risk in indicated patients. Cognitive complaints carry an FDA label warning but are not supported by randomized evidence.

Statin Intolerance Workup

True statin intolerance is uncommon, affecting roughly 5% of patients after proper rechallenge. The workup should proceed stepwise: first, rule out other causes of myalgias (hypothyroidism, vitamin D deficiency, drug interactions). Then rechallenge with the same or a different statin at a lower dose. Try an alternate statin, as rosuvastatin and pravastatin are the most hydrophilic and least likely to cause myalgias. Consider alternate-day dosing of a long-acting statin (rosuvastatin or atorvastatin). If the patient is truly intolerant after multiple trials, non-statin therapy becomes appropriate.

Non-Statin LDL-Lowering Therapies

Ezetimibe

Ezetimibe inhibits intestinal cholesterol absorption through the NPC1L1 transporter, reducing LDL by approximately 18 to 20% as monotherapy and 25% when added to a statin. The IMPROVE-IT trial demonstrated that ezetimibe plus simvastatin reduced cardiovascular events compared to simvastatin alone in post-ACS patients. Dosed at 10 mg daily with minimal side effects, ezetimibe is the first-line add-on when statin therapy alone does not achieve adequate LDL lowering.

PCSK9 Inhibitors

Evolocumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies that prevent PCSK9-mediated degradation of LDL receptors, increasing receptor recycling and dramatically lowering LDL by approximately 60% on top of statin therapy. The FOURIER and ODYSSEY OUTCOMES trials each demonstrated a 15% reduction in major adverse cardiovascular events. These agents are administered subcutaneously every two weeks or monthly. They are indicated for patients with clinical ASCVD and LDL of 70 or above despite maximally tolerated statin plus ezetimibe, or for heterozygous familial hypercholesterolemia not at goal. Cost remains a significant barrier at approximately $5,000 to $6,000 per year, and prior authorization is typically required.

Inclisiran

Inclisiran takes a gene-silencing approach, using small interfering RNA (siRNA) to target hepatic PCSK9 synthesis. It reduces LDL by approximately 50% on top of statin therapy. The major advantage is its dosing schedule: subcutaneous injection at baseline, three months, then every six months, administered in the clinic. The ORION trials demonstrated sustained LDL reduction, with a cardiovascular outcomes trial (ORION-4) ongoing.

Bempedoic Acid

Bempedoic acid inhibits ATP citrate lyase (ACL), blocking cholesterol synthesis upstream of HMG-CoA reductase. Critically, it is a prodrug activated in the liver but not in skeletal muscle, which explains why it avoids the myalgias associated with statins. It reduces LDL by approximately 18% as monotherapy and 38% when combined with ezetimibe (a fixed-dose combination is available). The CLEAR Outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events in statin-intolerant patients. It is dosed at 180 mg daily. Side effects include hyperuricemia (which can trigger gout) and rare tendon rupture. It is particularly well suited for statin-intolerant patients.

Bile Acid Sequestrants

Colesevelam, cholestyramine, and colestipol reduce LDL by 15 to 30% but are poorly tolerated due to gastrointestinal side effects (bloating, constipation) and interference with other medication absorption. They are rarely used for lipid lowering today. Colesevelam has an additional glucose-lowering effect in type 2 diabetes. These agents are contraindicated when triglycerides exceed 300 mg/dL, as they can paradoxically raise triglyceride levels.

Hypertriglyceridemia Management

Classification

Triglycerides are classified as normal (below 150 mg/dL), borderline high (150 to 199), high (200 to 499), and very high (500 or above, with pancreatitis risk).

Lifestyle Interventions (First-Line for All)

Weight loss of 5 to 10% reduces triglycerides by 20 to 30%. Refined carbohydrates and added sugars should be reduced. Alcohol, a major triglyceride contributor, should be limited or eliminated. Aerobic exercise of 150 minutes per week provides additional benefit. Secondary causes must be addressed: uncontrolled diabetes, hypothyroidism, and medications (thiazides, beta-blockers, oral estrogen, retinoids, corticosteroids).

Pharmacotherapy for Hypertriglyceridemia

Statins reduce triglycerides by 10 to 30% and are appropriate when ASCVD risk drives the treatment decision. Fibrates (fenofibrate preferred over gemfibrozil, which increases statin myopathy risk through a drug interaction) reduce triglycerides by 30 to 50% and are indicated for levels of 500 or above to prevent pancreatitis. The ACCORD Lipid trial found that fenofibrate plus simvastatin did not reduce cardiovascular events overall in type 2 diabetes, though a subgroup with high triglycerides and low HDL may benefit.

Icosapent ethyl (Vascepa) at 4 grams per day stands apart from other omega-3 products. The REDUCE-IT trial demonstrated a 25% reduction in cardiovascular events for patients with triglycerides 135 to 499 and established ASCVD or diabetes on a statin. Over-the-counter fish oil is not recommended for cardiovascular prevention, as it has no proven benefit and inconsistent purity. Icosapent ethyl is associated with a small increased risk of atrial fibrillation (NNH approximately 250). Niacin, despite its ability to lower triglycerides and LDL while raising HDL, has been largely abandoned because the AIM-HIGH and HPS2-THRIVE trials showed no cardiovascular benefit with increased side effects.

Familial Hypercholesterolemia (FH)

Recognition

FH should be suspected when LDL is 190 mg/dL or above in adults or 160 or above in children, when there is a family history of premature ASCVD, or when tendon xanthomas are present. The Dutch Lipid Clinic Network Score or Simon Broome criteria support clinical diagnosis. Heterozygous FH has a prevalence of approximately 1 in 250 and is significantly underdiagnosed. Homozygous FH, at approximately 1 in 300,000, often presents with LDL above 500 mg/dL and requires specialized therapy.

Management

High-intensity statin plus ezetimibe is first-line. Most heterozygous FH patients will need a PCSK9 inhibitor to reach LDL goals. Cascade screening of first-degree relatives is a public health imperative, as most FH patients remain undiagnosed. Children with confirmed heterozygous FH should begin statin therapy at age 8 to 10. Homozygous FH and treatment-refractory cases should be referred to a lipid specialist.

Coronary Artery Calcium (CAC) Scoring

CAC scoring is most useful for refining risk in patients with borderline ASCVD risk (5 to 20% 10-year risk). A CAC of 0 suggests very low near-term risk and may justify deferring statin therapy. A CAC of 100 or above, or at the 75th percentile or above for age and sex, favors statin initiation. It is not useful when statins are already indicated. Cost is typically $75 to $200 and is often not covered by insurance.

<image>A stepwise algorithm for managing LDL-C that is not at goal despite statin therapy. Start with maximally tolerated statin, then show sequential addition of ezetimibe, then PCSK9 inhibitor or inclisiran, with decision points based on ASCVD status, LDL threshold, and patient factors. Include expected LDL reduction percentage at each step and the key supporting trial for each therapy.</image>

<image>A mechanism-of-action diagram showing where each lipid-lowering drug class acts in the cholesterol metabolism pathway: statins and bempedoic acid in hepatic cholesterol synthesis, ezetimibe at intestinal absorption, PCSK9 inhibitors and inclisiran at LDL receptor recycling, bile acid sequestrants in enterohepatic circulation, and fibrates in triglyceride metabolism. Use a liver-intestine-blood vessel anatomical layout.</image>

<image>A clinical recognition infographic for familial hypercholesterolemia showing physical examination findings (tendon xanthomas on Achilles and hand extensors, xanthelasma, corneal arcus in patients under 45), the Dutch Lipid Clinic Network scoring criteria, and a family pedigree example demonstrating autosomal dominant inheritance pattern with cascade screening recommendations.</image>

Clinical Pearls

True statin intolerance is uncommon; most patients can tolerate an alternate statin or alternate-day dosing after a proper systematic workup. Bempedoic acid is ideal for statin-intolerant patients because its mechanism avoids activation in skeletal muscle, eliminating the myalgia problem. PCSK9 inhibitors achieve dramatic LDL reductions but cost and prior authorization remain significant barriers; inclisiran offers a clinic-administered alternative with less frequent dosing. Icosapent ethyl is the only omega-3 product with proven cardiovascular benefit; over-the-counter fish oil supplements should not be substituted. Lipoprotein(a) is a genetically determined, independent cardiovascular risk factor that should be measured once in a lifetime. CAC scoring is most useful for the "undecided" patient in the borderline risk category. In familial hypercholesterolemia, cascade screening of first-degree relatives is essential because the majority of affected individuals remain undiagnosed. Niacin is no longer recommended for cardiovascular risk reduction based on trial evidence showing no benefit with increased harm.

References

• Grundy SM et al. 2018 AHA/ACC Cholesterol Guideline. Circulation. 2019
• Cannon CP et al. IMPROVE-IT: Ezetimibe Added to Statin After ACS. NEJM. 2015
• Sabatine MS et al. FOURIER: Evolocumab in Patients with ASCVD. NEJM. 2017
• Nissen SE et al. CLEAR Outcomes: Bempedoic Acid in Statin-Intolerant Patients. NEJM. 2023
• Bhatt DL et al. REDUCE-IT: Icosapent Ethyl for CV Risk Reduction. NEJM. 2019
• Ray KK et al. ORION Trials: Inclisiran for LDL-C Lowering. NEJM. 2020
• Nordestgaard BG et al. Familial Hypercholesterolaemia: EAS Consensus Statement. Eur Heart J. 2013

Read this lecture as Markdown